Update shared on06 Aug 2025
Fair value Increased 6.38%Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33.
What's in the News
- Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.
- New data from the pivotal AUGMENT-101 trial of Revuforj (revumenib) showed a 26% complete remission/CRh rate and a 48% overall response rate in relapsed or refractory mNPM1 AML patients, with median overall survival of 4.8 months and higher survival in responders.
- In the AUGMENT-101 trial, CR+CRh responses with revumenib were observed regardless of co-mutations or prior therapy, and the treatment was generally well-tolerated.
- Revumenib demonstrated activity in R/R NUP98-rearranged AML, with a 60% remission rate in a small Phase 1 cohort and 100% overall response rate in the SAVE trial (n=5).
- Syndax Pharmaceuticals (NasdaqGS:SNDX) was added to multiple value-focused Russell Indexes, including the Russell 3000, 2000, 2500, Small Cap Comp, and 3000E Value Benchmarks/Indexes.
Valuation Changes
Summary of Valuation Changes for Syndax Pharmaceuticals
- The Consensus Analyst Price Target has risen from $32.67 to $34.33.
- The Consensus Revenue Growth forecasts for Syndax Pharmaceuticals has significantly fallen from 117.8% per annum to 87.5% per annum.
- The Future P/E for Syndax Pharmaceuticals has significantly fallen from 73.74x to 59.68x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.